Vertex Pharmaceuticals (Nasdaq: VRTX) gains FDA approval to expand Casgevy to children as young as two

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has received a supplemental approval from the U.S. Food and Drug Administration expanding Casgevy, its CRISPR/Cas9 gene-editing therapy, to patients as young as two years old with sickle cell disease or transfusion-dependent beta thalassemia. The decision makes Casgevy the first gene therapy authorized for children this young with sickle cell disease and extends an indication that had previously stopped at age twelve. Vertex shares closed near $497 on June 30, sitting inside a 52-week range of roughly $363 to $508, as the stock has already priced in a wave of positive pediatric data released earlier this year. The approval arrives on the back of a Commissioner’s National Priority Voucher, which compressed the FDA’s review clock and signals the agency’s continued willingness to fast-track therapies addressing high-priority public health needs. For Vertex, the expansion widens the addressable patient pool for a product that is central to the company’s post-cystic-fibrosis growth story.

What did the FDA actually approve for Casgevy in young children

The supplemental approval covers exagamglogene autotemcel, marketed as Casgevy, for patients aged two years and older with either sickle cell disease involving recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia. Casgevy was previously cleared only for patients twelve years and older. The FDA’s decision leans on trial data in the five-to-eleven age bracket combined with extrapolation to extend coverage down to age two, a regulatory pathway the agency uses when the underlying disease biology and treatment mechanism are considered consistent across the extended age range.

In the sickle cell portion of the pediatric trial, all eight efficacy-evaluable patients aged five to eleven achieved the study’s primary endpoint of being free from severe vaso-occlusive crises for at least twelve consecutive months. In the beta thalassemia arm, eight of nine efficacy-evaluable patients reached transfusion independence for twelve consecutive months, with a median duration of just over twenty months. Those figures are broadly consistent with the efficacy Vertex demonstrated in the original twelve-and-older population, where 29 of 31 evaluable patients hit the same freedom-from-crises benchmark. The consistency matters because it is the evidentiary basis regulators used to extrapolate downward to the two-to-four age cohort without requiring a fully separate pivotal study in that youngest group.

The clinical and regulatory read here extends beyond a simple label expansion. Sickle cell disease inflicts progressive organ damage that compounds with every year a patient goes untreated, and the standard of care for young children has historically been limited to transfusions, hydroxyurea, or a bone marrow transplant that depends on finding a matched donor. Casgevy’s extension to age two effectively repositions the therapy as an early intervention option rather than a late-stage rescue treatment, which could reshape how pediatric hematologists sequence care for newly diagnosed patients. It also raises execution questions Vertex has not yet fully answered, including how many of the roughly one hundred activated authorized treatment centers globally are equipped to perform myeloablative conditioning, the intensive pre-treatment chemotherapy step, safely in very young children.

How does this expansion change Vertex Pharmaceuticals’ commercial trajectory for Casgevy

Casgevy carries a U.S. list price around $2.2 million per patient, and Vertex retains all reported revenue from the therapy while sharing net profit economics with CRISPR Therapeutics AG under a 60/40 split favoring Vertex. Expanding eligibility to children as young as two enlarges the addressable population beyond the roughly 100,000 Americans living with sickle cell disease, since a meaningful share of eligible patients are diagnosed and symptomatic well before age twelve. Vertex’s first-quarter 2026 revenue rose 8.2% year over year to $2.99 billion, with Casgevy contributing to a growth mix that also includes cystic fibrosis franchise drugs, the newer ALYFTREK, and the non-opioid pain therapy JOURNAVX. Full-year 2026 guidance sits between $12.95 billion and $13.1 billion, with Vertex targeting over $500 million in revenue from products outside its legacy cystic fibrosis base.

Analyst sentiment has stayed constructive heading into this decision. Barclays and Morgan Stanley both raised price targets in early May, to $615 and $616 respectively, and the broader analyst consensus target sits closer to $549, implying continued upside from current levels even after the stock’s roughly 12% gain over the past month. Whether that optimism converts into near-term revenue depends less on regulatory clearance and more on real-world uptake. Casgevy’s commercial ramp since its original 2023 approval has been gradual, constrained by the multi-month process of stem cell collection, conditioning, and infusion at qualified treatment centers, and pediatric patients introduce additional complexity around dosing, caregiver logistics, and long-term monitoring commitments that could slow uptake even where clinical demand exists.

What competitive and reimbursement risks does the pediatric expansion introduce

Bluebird Bio’s Lyfgenia remains the primary alternative cell-based gene therapy for sickle cell disease, though it uses a lentiviral vector rather than CRISPR-based editing and carries a boxed warning related to blood cancer risk that has weighed on its uptake relative to Casgevy. Casgevy’s cleaner safety profile in the twelve-and-older population, with no reported cases of graft failure or graft rejection across treated patients, gives Vertex a competitive edge it will look to extend into the pediatric segment. The more consequential competitive question is whether earlier-line eligibility changes payer behavior. Extending treatment eligibility to two-year-olds increases the number of candidate patients insurers must evaluate for a therapy priced above $2 million, and value-based, outcomes-linked reimbursement agreements, the model Vertex has already negotiated in markets including Italy and with NHS England for adult indications, will likely become a template for pediatric coverage negotiations in the United States as well.

Regulatory momentum outside the United States adds another layer to the story. Vertex has completed submissions to expand Casgevy for younger patients in the United Kingdom and Saudi Arabia, positioning the company to convert similar pediatric data into approvals across multiple geographies within a relatively tight window. That global filing cadence reduces the risk that this approval represents a one-market win, but it also means Vertex’s near-term operating expenses tied to expanding authorized treatment center capacity and physician training will scale across several health systems simultaneously, a capital allocation consideration investors will watch alongside the company’s cystic fibrosis pipeline spending, including the recently discontinued VX-522 inhaled mRNA program.

Key takeaways on what the Casgevy pediatric approval means for Vertex, competitors, and the sickle cell treatment landscape

• Casgevy becomes the first gene therapy approved for sickle cell disease patients as young as two, expanding eligibility well below the original twelve-and-older threshold.
• The approval used an extrapolation pathway from five-to-eleven trial data rather than a dedicated pivotal study in two-to-four-year-olds, a faster but more judgment-dependent regulatory route.
• Vertex used a Commissioner’s National Priority Voucher to compress FDA review timing, reinforcing the value of that program as a competitive tool for future submissions.
• The addressable pediatric population sits below the roughly 100,000 Americans currently living with sickle cell disease, since many patients are diagnosed and symptomatic before age twelve.
• Vertex retains full reported Casgevy revenue while sharing net profit economics 60/40 with CRISPR Therapeutics AG, meaning volume growth flows disproportionately to Vertex’s top line.
• Analyst price targets from Barclays and Morgan Stanley, both above $600, suggest the sell side is pricing continued Casgevy and broader pipeline momentum into Vertex’s valuation.
• Bluebird Bio’s Lyfgenia remains the chief cell-based competitor, but its lentiviral mechanism and boxed cancer-risk warning leave Casgevy with a differentiated safety narrative for pediatric-focused prescribers.
• Treatment center capacity, myeloablative conditioning logistics, and caregiver burden are likely to gate real-world uptake more than regulatory eligibility alone.
• Reimbursement negotiations for pediatric use will test whether outcomes-based agreements already used in adult and international markets can scale to a broader, younger patient base.
• International filings underway in the United Kingdom and Saudi Arabia indicate Vertex is positioning this data package for a multi-market rollout rather than a single-geography win.